Study effect of MAPA-VIP on control of allergic asthma pathophysiology

INTRODUCTION: Asthma is a pulmonary disease and its pathogenesis is involved with immune cells and related signalling pathways.

Alpha-alumina is material for therapy applications and mucus adhesion promoting protein is cell-surface protein.

Vasoactive intestinal peptide (VIP) exerts immunomodulation.

Therefore, the drug delivery system and target binding molecule could be applicable for treatment of asthma.

MATERIAL AND METHODS: VIP-MapA-α-alumina was administered to asthmatic mice.

Then, eosinophil percentage, IgE, IL-4, IL-5, and IL-13 levels, GATA3, and MUC5AC gene expression, ROS and lung histopathology were studied.

RESULTS: Eosinophil percentage, IgE, IL-4, IL-5, IL-13, and ROS levels, expression of GATA3 and MUC5AC genes, goblet cell hyperplasia, mucus hyper-production, perivascular and peribronchial inflammation were decreased in VIP and VIP-MapA treated groups and treatment with VIP-MapA has a stronger effect than VIP alone.

CONCLUSIONS: The delivery system of VIP carrying to the lung with the use of MapA as an adhesion molecule, could easily carry VIP and led to penetration of this component to the mucus and reach bronchial cells and present an effective, strong, and long-acting effect on therapy of asthma.